Vaccine: a substance used to stimulate the production of antibodies and provide immunity against one or several diseases, prepared from the causative agent of a disease, its products, or a synthetic substitute, treated to act as an antigen without inducing the disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and recognize and destroy any of these microorganisms that it later encounters.
Date: May 5, 2021 Time: 8:00am PDT, 11:00am EDT Emergence of genetic mutations within the SARS-CoV-2 genome that may enhance transmissibility, increase symptom severity or improve the virus...
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
The SARS-CoV-2 pandemic is challenging our health care systems and has profoundly impacted our society. Due to the poor global public health response, SARS-CoV-2 has developed many variants....
Controlling the spread of the 2019 novel coronavirus SARS-CoV-2 and ensuring a return to 'normal' activities in a post-COVID world requires two complementary efforts: 1) Widespread a...
As the SARS-CoV-2 continues to spread and evolve and vaccination efforts are under way, countries around the world are confronting new public health challenges due to the emergence and rapid...
Since late 2020, several prominent SARS-CoV-2 variants of concern have emerged harboring specific mutations which increase viral transmissibility (e.g., lineage B.1.1.7), and which appear to...
This presentation will focus on strategies for the design and validation of robust assays for the detection of SARS-CoV-2, including nucleic acid extraction, multiplexed qPCR assays, and int...
The COVID19 pandemic continues to be a major epidemiological challenge across the globe. Part of the challenge, often seen with viruses, is that the nucleic acid genome quickly mutates, prod...
Despite available vaccines and treatments, COVID-19 continues to impose a major burden in the world, as a leading cause of hospitalizations and deaths. We and others have been working in te...
Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who ha...
Date: April 14, 2021 Time: 9:00am PDT Testing solutions for CoV-2 have had to evolve as the pandemic creates challenges and opportunities for various technologies to support the ongoing nee...
The Institute for Health Metrics and Evaluation (IHME) uses a hybrid modeling approach to generate Covid19 forecasts. The model incorporates elements of statistical and disease transmission...
COVID 19 is caused by a new coronavirus , SARS-CoV-2, which is highly infectious and can cause a wide spectrum of symptoms and affect multiple human systems. What we have learned from other...
Vaccines to prevent COVID-19 were developed within 1 year after the identification of SARS-CoV-2 as the causative virus. There are now 3 vaccines that are FDA approved via Emergency Use Auth...
Over a year into the COVID-19 pandemic, key vulnerable populations in the United States and across the world lack access to effective vaccines. IDRI has developed technology that addresses s...
Despite a continuous decline of corona virus cases, the broad rollout of multiple vaccines, and the start of a return to normalcy, concerns of SARS-CoV-2 outbreaks continue to linger on the...
One challenge pharmaceutical companies face, is moving promising biotherapeutic products into the clinic as fast as safely possible. Devoting the correct amount of time and resources to earl...
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
Date: March 24, 2021 Time: 9:00am (PST), 12:00pm (EST) Determination of residual host cell DNA and RNA are regulatory expectations as they pose potential safety concerns for cell culture-der...
Date: March 22, 2021 Time: 8:00am PDT, 11:00am EDT Viral diversity presents an ongoing challenge for diagnostic tests, which must be designed to accurately detect all current and future circ...
DATE: March 09, 2021 TIME: 08:00am PST The COVID-19 pandemic has placed urgency on precise analysis of rare antigen- and virus-specific T cells. At Miltenyi Biotec, we offer a complete workf...
The COVID-19 pandemic changed all of our lives in 2020. Development of a COVID-19 vaccine required some re-thinking of the standard vaccine development paradigm. The webinar will cover noncl...
Platform based therapeutics and vaccines offer a unique opportunity to simplify and streamline the drug development process. Moderna has taken the approach of harnessing the power of mRNA as...
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...
Date: May 5, 2021 Time: 8:00am PDT, 11:00am EDT Emergence of genetic mutations within the SARS-CoV-2 genome that may enhance transmissibility, increase symptom severity or improve the virus...
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
The SARS-CoV-2 pandemic is challenging our health care systems and has profoundly impacted our society. Due to the poor global public health response, SARS-CoV-2 has developed many variants....
Controlling the spread of the 2019 novel coronavirus SARS-CoV-2 and ensuring a return to 'normal' activities in a post-COVID world requires two complementary efforts: 1) Widespread a...
As the SARS-CoV-2 continues to spread and evolve and vaccination efforts are under way, countries around the world are confronting new public health challenges due to the emergence and rapid...
Since late 2020, several prominent SARS-CoV-2 variants of concern have emerged harboring specific mutations which increase viral transmissibility (e.g., lineage B.1.1.7), and which appear to...
This presentation will focus on strategies for the design and validation of robust assays for the detection of SARS-CoV-2, including nucleic acid extraction, multiplexed qPCR assays, and int...
The COVID19 pandemic continues to be a major epidemiological challenge across the globe. Part of the challenge, often seen with viruses, is that the nucleic acid genome quickly mutates, prod...
Despite available vaccines and treatments, COVID-19 continues to impose a major burden in the world, as a leading cause of hospitalizations and deaths. We and others have been working in te...
Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who ha...
Date: April 14, 2021 Time: 9:00am PDT Testing solutions for CoV-2 have had to evolve as the pandemic creates challenges and opportunities for various technologies to support the ongoing nee...
The Institute for Health Metrics and Evaluation (IHME) uses a hybrid modeling approach to generate Covid19 forecasts. The model incorporates elements of statistical and disease transmission...
COVID 19 is caused by a new coronavirus , SARS-CoV-2, which is highly infectious and can cause a wide spectrum of symptoms and affect multiple human systems. What we have learned from other...
Vaccines to prevent COVID-19 were developed within 1 year after the identification of SARS-CoV-2 as the causative virus. There are now 3 vaccines that are FDA approved via Emergency Use Auth...
Over a year into the COVID-19 pandemic, key vulnerable populations in the United States and across the world lack access to effective vaccines. IDRI has developed technology that addresses s...
Despite a continuous decline of corona virus cases, the broad rollout of multiple vaccines, and the start of a return to normalcy, concerns of SARS-CoV-2 outbreaks continue to linger on the...
One challenge pharmaceutical companies face, is moving promising biotherapeutic products into the clinic as fast as safely possible. Devoting the correct amount of time and resources to earl...
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
Date: March 24, 2021 Time: 9:00am (PST), 12:00pm (EST) Determination of residual host cell DNA and RNA are regulatory expectations as they pose potential safety concerns for cell culture-der...
Date: March 22, 2021 Time: 8:00am PDT, 11:00am EDT Viral diversity presents an ongoing challenge for diagnostic tests, which must be designed to accurately detect all current and future circ...
DATE: March 09, 2021 TIME: 08:00am PST The COVID-19 pandemic has placed urgency on precise analysis of rare antigen- and virus-specific T cells. At Miltenyi Biotec, we offer a complete workf...
The COVID-19 pandemic changed all of our lives in 2020. Development of a COVID-19 vaccine required some re-thinking of the standard vaccine development paradigm. The webinar will cover noncl...
Platform based therapeutics and vaccines offer a unique opportunity to simplify and streamline the drug development process. Moderna has taken the approach of harnessing the power of mRNA as...
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...
Follow
